---
title: Treatment and prognosis-Aplastic anemia
---

# Treatment and prognosis-Aplastic anemia

## Immunosuppression

### CsA/tacrolimus, ATG antithymocyte immunoglobulin

- 70-80% respond
- 80-90% 5-y survival
  - (96% vs. 76% w/ horse vs. rabbit ATG; NEJM 2011;365:430);
- 15-20% 10-y incidence of clonal disorders
  - (mostly MDS, AML, PNH)
- Anti-lymphocyte, [[anti-thymocyte globulin]] (ALG,ATG)

## TPO mimetics (eg, eltrombopag)

- 1st-line w/ immunosuppression
  (NEJM 2022;386:11)

## Supportive care

- transfusions : bleeding 或血小板<5,000-10,000/μL 就要輸血
- abx
- possible utility of G-CSF
- Epo (if Epo <500)

### Allogeneic HSCT

- young Pts

  - → ~80% long-term survival
  - ↓ risk malignant, but has
  - risk of transplant-related m&m

- if possible,
  - avoid transfusions : risk of alloimmunization @ pretransplant
